<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125943</url>
  </required_header>
  <id_info>
    <org_study_id>BVZAch</org_study_id>
    <nct_id>NCT01125943</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Endothelium Dependent Vasodilation</brief_title>
  <official_title>Bevacizumab and Endothelium Dependent Vasodilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The introduction of angiogenesis inhibitors has remarkably improved treatment of patients
      with several types of cancer. One of the most reported side effects of angiogenesis
      inhibitors is hypertension. In patients treated with bevacizumab, a monoclonal antibody
      against vascular endothelial growth factor, hypertension had an overall incidence up to 32%.
      The increase in blood pressure occurs early in treatment. The etiology of hypertension caused
      by treatment with angiogenesis inhibitors is unclear. Understanding the pathogenesis of this
      side effect is essential for optimal treatment with this class of drugs.

      The primary objective is to explore the effect of bevacizumab infusion on
      endothelium-dependent vasodilation of forearm resistance arteries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasomotor response assessed by venous occlusion strain gauge plethysmography</measure>
    <time_frame>15 minutes</time_frame>
    <description>Response to infusion of bevacizumab and/or acetylcholin or nitroprusside</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <condition>Cancer</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Acetylcholine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitroprusside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcholine</intervention_name>
    <description>Intra-arterial infusion</description>
    <arm_group_label>Acetylcholine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroprusside</intervention_name>
    <description>Intra arterial infusion</description>
    <arm_group_label>Nitroprusside</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intra arterial infusion</description>
    <arm_group_label>Acetylcholine</arm_group_label>
    <arm_group_label>Nitroprusside</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-50 years old

          2. Male

          3. Results of serum glucose, lipids and creatinine should be within the laboratory's
             reference ranges.

          4. Subject is able and willing to sign the Informed Consent Form prior to screening
             evaluations.

        Exclusion Criteria:

          1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.

          2. History of or current abuse of drugs, alcohol or solvents.

          3. History of malignant disease.

          4. First degree relatives with a history of cancer before the age of 50

          5. First degree relatives with a history of premature cardiovascular disease before the
             age of 50

          6. Current use of medication.

          7. Clinical evidence of cardiac or pulmonary disease

          8. Hypertension ( systole &gt;140mmHG, diastole &gt;90mmHg)

          9. Diabetes mellitus

         10. Smoking

         11. Any clinically relevant abnormality on ECG.

         12. A history of thrombosis or first degree family members with a history of recurrent
             thrombosis

         13. Inability to understand the nature and extent of the trial and the procedures
             required.

         14. Previous participation in a study with bevacizumab
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>G. Rongen</investigator_full_name>
    <investigator_title>Prof dr. G. Rongen</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Acetylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

